On Jun. 8, 2021, Pfizer announced that the U.S. Food and Drug Administration (FDA) had approved PREVNAR 20ﾙ (Pneumococcal 20-valent Conjugate Vaccine) for the prevention of invasive disease and pneumonia caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes in the vaccine in adults ages 18 years and older.

The U.S. Centers for Disease Control and Preventionﾒs (CDC) Advisory Committee on Immunization Practices (ACIP) was expected to meet in October to discuss and update recommendations on the safe and appropriate use of pneumococcal vaccines in adults.